The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 1, 2013, Pages 91-97

  Cabrera, R ^a   Limaye, A R ^a   Horne, P ^a   Mills, R ^a   Soldevila Pico, C ^a   Clark, V ^a   Morelli, G ^a   Firpi, R ^a   Nelson, D R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG POTENCY; FEMALE; GENOTYPING TECHNIQUE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS LOAD;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84870609621     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12098     Document Type: Article

References (23)

1. McGlynn KA, London WT,. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011; 15: 223-43.
2. Kanwal F, Hoang T, Kramer JR, et al,. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140: 1182-8.
3. Bruix J, Sherman M,; American Association of the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
4. Llovet JM, Ricci S, Mazzaferro V, et al,.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
5. Cheng AL, Kang YK, Chen Z, et al,. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
6. Bolondi L, Caspary W, Bennouna J, et al,. Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): subgroup analysis of the SHARP trial. [Abstract] Presented at the 2008 Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008.
7. Arrondeau J, Mir O, Boudou-Rougette P, et al,. Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Invest New Drugs 2012; 30: 2046-9.
8. Himmesbach K, Sauter D, Baumert TF, et al,. New aspects of an anti-tumor drug: sorafenib efficienty inhibits HCV replication. Gut 2009; 58: 1644-53.
9. Mee CJ, Farquhar MJ, Harris HJ, et al,. Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. Gastroenterology 2010; 138: 1134-42.
10. Cabrera R, Nelson DR,. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 31: 461-76.
11. Lencioni R, Llovet JM,. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
12. Velosa J, Serejo F, Marinho R, et al,. Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis. Dig Dis Sci 2011; 56: 1853-61.
13. Hezode C, Dorival C, Zoulim F, et al,.; ANRS CO20 CUPIC study group. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non-responders. First results of the French Early Access Program (ANRS CO20-CUPIC). Abstract #8, Presented at European Association for the Study of the Liver (EASL 2012). Barcelona, April 22, 2012.
14. Chaparro M, Gonzalez Moreno L, Trapero-Marugan M, et al,. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment Pharmacol Ther 2008; 28: 1269-77.
15. Pinter M, Sieghart W, Hucke F, et al,. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011; 34: 949-59.
16. Hollebecque A, Cattan S, Romano O, et al,. Safety and efficacy of sorafenib in hepatocellular carcinoma: the imact of the Child-Pugh score. Aliment Pharmacol Ther 2012; 35: 83-91.
17. Burckstummer T, Kriegs M, Lupberger J, et al,. Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication. FEBS Lett 2006; 580: 575-80.
18. Bardou-Jacquet E, Lorho R, Guyader D,. Kinase inhibitors in the treatment of chronic hepatitis C virus. Gut 2011; 60: 879-80.
19. Reiberger T, Angermayr B, Schwabl P, et al,. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol 2009; 51: 865-73.
20. Hennenberg M, Trebicka J, Stark C, et al,. Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol 2009; 157: 258-70.
21. Hidaka H, Nakazawa T, Kaneko T, et al,. Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study. J Gastroenterol 2012; 47: 1030-5.
22. Pinter M, Sieghart W, Reiberger T, et al,. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma-a pilot study. Aliment Pharmacol Ther 2012; 35: 83-91.
23. Coriat R, Gouya H, Mir O, et al,. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib. PLoS ONE 2011; 6: e16978.